Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 13/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13475725 | 0.89 | ACE (0.54) | ACEF2 | |
| SCHEMBL8230028 | 0.89 | ACE (0.54) | ACEF2 | |
| SCHEMBL1443345 | 0.89 | ACE (0.54) | ACEF2 | |
| SCHEMBL13409464 | 0.86 | F2 (0.46) | ACEF2PRSS1 | |
| SCHEMBL3692081 | 0.82 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL3692085 | 0.82 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL22409423 | 0.82 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL5900836 | 0.82 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL5900839 | 0.82 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 | |
| SCHEMBL8378100 | 0.82 | ACE (0.77) | ACEF2PRSS1CMA1KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-7667044-B2 | treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases | PROBIODRUG AG (DE) | 2010-02-23 | — | — | US | disclosed |
| US-7667044-B2 | treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases | PROBIODRUG AG (DE) | 2010-02-23 | — | — | US | disclosed |
| WO-2006058720-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PREP, BACE1, BCHE | ACE 147/4885F2 1879/4885PRSS1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.